Development and validation of an immune-related gene-based prognostic signature in gastric cancer

P. Ge,Xiaofang Chen,Yang Wu,Yu-bin Fu,Chun-bo Li,Zhen-Hua Feng,Ji-Xin Xue,Lin Li,Gong Zhang,Zhi-qiang Gao,X. Dang
DOI: https://doi.org/10.21203/rs.2.22778/v1
2020-02-06
Abstract: Background: Gastric cancer is a common lethal cancer worldwide. We aimed to develop a reliable, individualized, immune-related prognostic signature that can be used to stratify and estimate prognosis in patients with gastric cancer. Methods: This retrospective study analyzed the gene expression profiles of gastric cancer with tumor tissue samples from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) cohorts, which included 676 cases in total. Immune genes from the InnateDB database were selected to develop and validate an immune-related prognostic model for gastric cancer patients. Results: An immune-related gene pair (IRGP) model was constructed that enabled us to stratify patients into high- and low-risk immune risk groups in the training set. Patients with a low risk score had a significantly longer median survival time than those with a high risk score. Further, we compared the predictive accuracy of the IRGP model with clinical characteristics, including TNM, grade, age, and stage. The results showed that the model had the highest mean C-index (0.69) compared with grade (0.55) or stage (0.60) in survival prediction. Then, we constructed a nomogram that integrated the IRGP model with independent clinical characteristics, which showed the best prognostic accuracy compared with other signatures. Conclusion: A clinical-immune signature based on IRGP is a promising prognostic biomarker in gastric cancer. Prospective studies are needed to further validate its accuracy and to test its clinical utility in individualized treatment.
What problem does this paper attempt to address?